Trial Profile
A clinical study of tropifexor in combination of one or more Pfizer compounds for the treatment of NASH
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2018
Price :
$35
*
At a glance
- Drugs Clesacostat (Primary) ; Ervogastat (Primary) ; PF 06835919 (Primary) ; Tropifexor (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 05 Nov 2018 New trial record
- 29 Oct 2018 According to a Novartis media release, the company went under the agreement with Pfizer to initiate this combination study with Pfizer drugs.